Elekta will publish its interim report for May-January 2013/14 on February 27 as per:

-- The report will be published at 07:30 CET.

-- Elekta will host a telephone conference at 10:00-11:00 CET with Tomas Puusepp, President and CEO and Håkan Bergström, CFO.

To take part in the conference call, please dial in about five minutes in advance, use the telephone numbers below and the access code 941615.

-- UK dial-in number: +44 (0)20 7162 0077

-- US dial-in number: +1 877 491 0064

-- Swedish dial-in number: +46 (0)8 5052 0110

The telephone conference will be broadcasted live online (for the possibility to ask questions, please also dial in). Please use the link:

http://webeventservices.reg.meeting-stream.com/84836_elekta/

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.

http://mb.cision.com/Main/35/9535948/209843.pdf

This information was brought to you by Cision http://news.cision.com

For further information, please contact:
Johan Andersson, Director Investor Relations, Elekta AB.
Tel: +46 702 100 451, email: johan.andersson@elekta.com
or
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, email: tobias.bulow@elekta.com